West Virginia First Foundation recognizes grant recipients fighting substance use crisis
The WVFF opened up applications for the grant around eight months ago, and Tuesday marked the end of the grant period in which the WVFF awarded $17 million to 94 projects throughout West Virginia to address substance use disorder.
The recipients, including non-profits, community organizations, local governments and law enforcement, gathered Tuesday to be recognized.
CJIS holds memorial ceremony for fallen West Virginia law enforcement officers
'We're celebrating the doers of the state, the people that are the tip of the spear. They've gone through a very challenging and robust application process and they've proven the worth of these projects. They are all so valuable and these are the folks that take these tools that we can provide and get them back into the communities,' Jonathan Board, Executive Director of West Virginia First Foundation, said
Several times throughout the event, speakers mentioned how there was a 43% decrease in overdose deaths in West Virginia in 2024, but the West Virginia First Foundation said that there's still a lot of work to be done.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Electrophysiology Market worth US$21.72 billion by 2030 with 11.6% CAGR
DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Electrophysiology Market, valued at US$11.41 billion in 2024, stood at US$12.55 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2025 to 2030, culminating in a forecasted valuation of US$21.72 billion by the end of the period. The rise of the electrophysiology market can be attributed to several drivers: the increasing prevalence of cardiovascular diseases, including arrhythmias and atrial fibrillation; patients and healthcare providers are increasingly favoring minimally invasive procedures over traditional surgical interventions; electrophysiological techniques, such as catheter ablation, offer less invasive options for treating certain cardiac arrhythmias; and government support and initiatives aimed at improving healthcare infrastructure and funding research and development in electrophysiology also contribute to market growth. Download PDF Brochure: Browse in-depth TOC on "Electrophysiology Market" 322 - Tables62 - Figures330 - Pages By product, in 2024, electrophysiology ablation catheters are expected to be the leading segment in the medical device market. This anticipated growth is largely driven by the rising global prevalence of atrial fibrillation (AF) and various cardiac arrhythmias, which has increased the demand for minimally invasive ablation techniques. Recent technological advancements in catheter design, such as the introduction of contact force-sensing mechanisms, irrigated-tip designs, and high-power short-duration (HPSD) ablation systems, have greatly enhanced procedural safety, precision, and clinical outcomes. These innovations are contributing to wider acceptance and increased utilization of these catheters within the medical community. By indication, the electrophysiology market, divided by medical indications, includes segments such as atrial fibrillation, atrial flutter, and atrioventricular nodal reentry tachycardia. Atrial flutter, characterized by rapid heartbeats from the atria, is increasingly common, especially among the elderly, due to age-related cardiac changes. This rising prevalence has created a demand for advanced diagnosis and treatment options tailored to atrial flutter. Innovations in catheter ablation, advanced imaging techniques, and new pharmacological therapies reflect the urgency for effective arrhythmia management in an aging population. By geography, in 2024, North America, primarily the US and Canada, is set for significant growth in the medical technology market. The region is a global leader in medical innovations, especially in electrophysiology, often adopting breakthroughs ahead of others. With some of the highest healthcare spending globally, the US influences the uptake of advanced medical technologies, enhancing patient outcomes and operational efficiency. Strong A investment in research and development fosters innovation and creates a robust marketplace for new products and services, solidifying North America's role as a key driver of growth in the medical technology sector. Request Sample Pages : As of 2024, prominent players in the electrophysiology market are Johnson & Johnson Services, Inc. (US), Abbott (US), Medtronic (Ireland), Koninklijke Philips N.V. (Netherlands), GE Healthcare (US), Boston Scientific Corporation (US), Japan Lifeline Co., Ltd (Japan), Stereotaxis, Inc. (US), MicroPort Scientific Corporation (China), and BIOTRONIK (Germany). Abbott (US): Abbott Laboratories is a comprehensive healthcare company that operates across diverse sectors, including pharmaceuticals, medical devices, diagnostics, and nutrition. The company has established a significant presence in electrophysiology, particularly in the development of advanced medical devices for cardiac electrophysiology procedures. Abbott's portfolio in this specialized market includes sophisticated mapping systems, electrophysiology catheters, and related technologies designed for the precise diagnosis and management of cardiac arrhythmias. Furthermore, Abbott is likely engaged in ongoing research and development initiatives aimed at innovating and enhancing electrophysiological technologies to improve patient outcomes and procedural efficiencies. Koninklijke Philips N.V. (Netherlands) Koninklijke Philips N.V. Philips, a Netherlands-based multinational company, is a significant player in the healthcare sector, particularly within medical technology. The company develops an extensive range of products that enhance capabilities in cardiology, patient monitoring, diagnostic imaging, and electrophysiology. In the electrophysiology domain, Philips offers advanced solutions aimed at the identification and management of cardiac arrhythmias. This product suite includes high-precision imaging technologies, advanced mapping systems, and specialized electrophysiology catheters, all essential tools utilized by cardiology professionals. Key offerings include the EP WorkMate system, which serves as a comprehensive electrophysiology recording and reporting platform, facilitating efficient data capture and analysis during procedures. Additionally, Philips has introduced state-of-the-art X-ray imaging systems designed for enhanced visualization during electrophysiological interventions. The EP Navigator and EP-XT Mapping system are also part of their innovative portfolio, providing clinicians with advanced three-dimensional mapping capabilities that improve procedural accuracy and patient outcomes. For more information, Inquire Now! Related Reports: Defibrillator Market Cardiac Monitoring & Cardiac Rhythm Management Devices Market Ablation Technology Market Catheters Market Digital X-ray Market Get access to the latest updates on Electrophysiology Companies and Electrophysiology Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets
Yahoo
14 minutes ago
- Yahoo
UnitedHealth stock pops on Buffett's Berkshire share purchase
UnitedHealth Group's (UNH) stock jumped early Friday after Warren Buffett's Berkshire Hathaway (BRK-A, BRK-B) revealed Thursday it purchased 5 million shares last quarter. The insurance giant has suffered multiple setbacks in the past couple of years — with earnings misses piling on top of all that, the stock has been under constant pressure, and is down more than 45% year-to-date. But on the news of Berkshire's share purchase, the stock popped nearly 10% in early trading Friday. The last time Berkshire held a stake in the company was when Stephen Hemsley was CEO, between 2006 and 2017. Hemlsey has returned to the role after former CEO Andrew Witty stepped down in May — after a year of compounding headwinds. Last year, the company suffered one of the biggest cyberattacks in history on one of it's subsidiaries, Change Healthcare, which manages payments — creating havoc for health providers for months. The US Health and Human Services Department (HHS) had to step in and assist to help get payments flowing again. The company subsequently announced a larger-than-expected impact from the attack in mid-2024, dragging down major indices. At the end of the year, during the annual shareholder's meeting in New York City, insurance CEO Brian Thompson was shot to death. The struggles for the company didn't end there, as public backlash against the industry swelled in the aftermath, and the entire insurance industry was forced to address the issue of denied claims. In April this year, the company's stock crashed after an earnings miss shocked the Street. In May, Hemsley took over, and in the latest earnings call addressed the missteps the company has made, as well as the higher cost environment that it did not adjust in time to. "Beyond the environmental factors that are affecting the entire sector and more specifically to us, we have made pricing and operational mistakes as well as others," he said on the call. UnitedHealth's stock pop also helped boost the Dow (DJI), which was up about a half percent in early trading. Previously, UnitedHealth's losses dragged the Dow. In May, UnitedHealth was attributed with 88% of the Dow's decline year-to-date. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 minutes ago
- Yahoo
Buffett Just Bought the Dip--Is This Health Giant the Comeback Play of the Year?
UnitedHealth Group (NYSE:UNH) just caught a lifelinestraight from two of Wall Street's most respected investors. Shares jumped 8.75% at 9.31am today, marking the stock's biggest intraday gain since 2020. The catalyst? Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway disclosed a fresh 5 million-share stake, while David Tepper (Trades, Portfolio)'s Appaloosa Management added another 2.3 million shares. That's a bold vote of confidence for a company that's been hammered this year, down 46% amid regulatory heat and earnings disappointments. Warning! GuruFocus has detected 5 Warning Sign with UNH. The health insurance heavyweight is navigating one of the roughest stretches in its history. A top executive was murdered late last year. In April, the company slashed its full-year outlook, then replaced its CEO with former chief Stephen Hemsley. Most recently, UnitedHealth issued a fresh profit forecast that came in below every single analyst estimatea stunning reversal for a business that had beaten expectations for over 60 straight quarters. So what broke the streak? UnitedHealth underestimated how quickly Americans would return to using medical servicesand set premiums too low as a result. Meanwhile, changes in government-subsidized coverage and payment models are eating into margins. If this trend holds, 2025 could mark the first annual adjusted EPS decline in nearly 20 years. Still, Buffett and Tepper stepping in suggests they see something others don't: a dominant business under temporary pressure, with long-term upside hiding in the wreckage. This article first appeared on GuruFocus.
